Ipsen SA

Ipsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

07 май 2024 07:55:54 Источник Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 май 2024 11:00:00 Источник Nasdaq GlobeNewswire

Ipsen appoints Keira Driansky as EVP, President of North America

02 май 2024 00:30:00 Источник Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

24 апр 2024 00:00:00 Источник Nasdaq GlobeNewswire

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

22 апр 2024 00:00:00 Источник Nasdaq GlobeNewswire

Ipsen publishes its 2023 Universal Registration Document

17 апр 2024 11:00:00 Источник Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

08 апр 2024 11:00:00 Источник Nasdaq GlobeNewswire

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

02 апр 2024 00:00:00 Источник Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07 мар 2024 11:00:00 Источник Nasdaq GlobeNewswire

Ipsen S.A. publishes its 2023 Consolidated Financial Statements

15 фев 2024 03:00:45 Источник Nasdaq GlobeNewswire

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA  

13 фев 2024 15:08:23 Источник Nasdaq GlobeNewswire

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

07 фев 2024 23:58:00 Источник Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06 фев 2024 11:00:00 Источник Nasdaq GlobeNewswire

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

22 янв 2024 16:00:00 Источник Nasdaq GlobeNewswire

Ipsen – Half year statement – 2023 12 31

08 янв 2024 11:00:00 Источник Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

05 янв 2024 11:00:00 Источник Nasdaq GlobeNewswire

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

07 дек 2023 11:49:00 Источник Nasdaq GlobeNewswire

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

07 дек 2023 00:00:00 Источник Nasdaq GlobeNewswire

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

07 дек 2023 00:00:00 Источник Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023

14 ноя 2023 11:00:00 Источник Nasdaq GlobeNewswire